While most eyes were on the election on Tuesday evening, Arrowhead Pharmaceuticals Inc ARWR provided an update on their Heparc-2004 clinical study of ARC-520. In an 8:05 p.m. press release, the company announced the study was verbally put on hold by the FDA following deaths in non-human primates.
In trading Wednesday, the share price dropped more than 25 percent following the news. Cantor Fitzgerald analyst Elemer Piros, however, reiterated a Buy rating and a $15 price target in a research note addressing the previous evening’s press release.
Piros’ key reasoning was the deaths occurred at the highest dose, and the carrier molecule, EX1, appeared to be the culprit. Thirdly, the study was placed on hold only in the United States.
“Six other trials in Europe, Asia and Australia are continuing to dose up to around 300 patients,” said Piros.
At last check, Arrowhead was down 28.15 percent at $4.39.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.